NAPHTHALENIC LIGNAN LACTONES AS SELECTIVE, NONREDOX 5-LIPOXYGENASE INHIBITORS - SYNTHESIS AND BIOLOGICAL-ACTIVITY OF (METHOXYALKYL)THIAZOLE AND METHOXYTETRAHYDROPYRAN HYBRIDS

被引:32
作者
DUCHARME, Y
BRIDEAU, C
DUBE, D
CHAN, CC
FALGUEYRET, JP
GILLARD, JW
GUAY, J
HUTCHINSON, JH
MCFARLANE, CS
RIENDEAU, D
SCHEIGETZ, J
GIRARD, Y
机构
[1] Merck Frosst Centre for Therapeutic Research, Québec, H9R 4P8, P.O. Box 1005, Pointe Claire-Dorval
[2] Merck Research Laboratories, West Point
关键词
D O I
10.1021/jm00030a010
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Combinations of structural elements found in (methoxyalkyl)thiazole 1a and methoxytetrahydropyran 2a with a naphthalenic lignan lactone produce the potent 5-lipoxygenase (5-LO) inhibitors 3 and 4. While the nature of link Y-Z has a major effect on the in vitro activity of compounds 1 and 2, inhibitors 3 and 4 retain their potencies with either an oxymethylene (Y = O, Z = CH2) or a methyleneoxy (Y = CH2, Z = O) link. Compound 4b inhibits the oxidation of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid by 5-LO (IC50 = 14 nM) and the formation of leukotriene Bq in human polymorphonuclear leukocytes (IC50 = 1.5 nM) as well as in human whole blood (IC50 = 50 nM). Compound 4b is a selective 5-LO inhibitor showing no significant inhibition of human 15-lipoxygenase or porcine 12-lipoxygenase or binding to human 5-lipoxygenase-activating protein up to 10 mu M and inhibits leukotriene biosynthesis by a direct, nonredox interaction with 5-LO. Compound 15, the open form of lactone 4b, is well absorbed in the rat and is transformed into the active species 4b. In addition, 15 is orally active in the rat pleurisy model (ED(50) = 0.6 mg/kg) and in the functional model of antigen-induced bronchoconstriction in allergic squirrel monkeys (95% inhibition at 0.3 mg/kg).
引用
收藏
页码:512 / 518
页数:7
相关论文
共 19 条
  • [1] BEL E H, 1990, American Review of Respiratory Disease, V141, pA31
  • [2] (METHOXYALKYL)THIAZOLES - A NEW SERIES OF POTENT, SELECTIVE, AND ORALLY ACTIVE 5-LIPOXYGENASE INHIBITORS DISPLAYING HIGH ENANTIOSELECTIVITY
    BIRD, TGC
    BRUNEAU, P
    CRAWLEY, GC
    EDWARDS, MP
    FOSTER, SJ
    GIRODEAU, JM
    KINGSTON, JF
    MCMILLAN, RM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) : 2176 - 2186
  • [3] PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR
    BRIDEAU, C
    CHAN, C
    CHARLESON, S
    DENIS, D
    EVANS, JF
    FORDHUTCHINSON, AW
    FORTIN, R
    GILLARD, JW
    GUAY, J
    GUEVREMONT, D
    HUTCHINSON, JH
    JONES, TR
    LEGER, S
    MANCINI, JA
    MCFARLANE, CS
    PICKETT, C
    PIECHUTA, H
    PRASIT, P
    RIENDEAU, D
    ROUZER, CA
    TAGARI, P
    VICKERS, PJ
    YOUNG, RN
    ABRAHAM, WM
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) : 799 - 807
  • [4] PALLADIUM-CATALYZED CARBONYLATION OF ARYL TRIFLATES - SYNTHESIS OF ARENECARBOXYLIC ACID-DERIVATIVES FROM PHENOLS
    CACCHI, S
    CIATTINI, PG
    MORERA, E
    ORTAR, G
    [J]. TETRAHEDRON LETTERS, 1986, 27 (33) : 3931 - 3934
  • [5] CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929
  • [6] CHARLESON S, 1992, MOL PHARMACOL, V41, P873
  • [7] METHOXYTETRAHYDROPYRANS - A NEW SERIES OF SELECTIVE AND ORALLY POTENT 5-LIPOXYGENASE INHIBITORS
    CRAWLEY, GC
    DOWELL, RI
    EDWARDS, PN
    FOSTER, SJ
    MCMILLAN, RM
    WALKER, ERH
    WATERSON, D
    BIRD, TGC
    BRUNEAU, P
    GIRODEAU, JM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (14) : 2600 - 2609
  • [8] DENIS D, 1991, J BIOL CHEM, V266, P5072
  • [9] N-(4-CHLOROPHENYL)-N-HYDROXY-N'-(3-CHLOROPHENYL)UREA, A GENERAL REDUCING AGENT FOR 5-LIPOXYGENASES, 12-LIPOXYGENASES, AND 15-LIPOXYGENASES AND A SUBSTRATE FOR THEIR PSEUDOPEROXIDASE ACTIVITIES
    FALGUEYRET, JP
    DESMARAIS, S
    ROY, PJ
    RIENDEAU, D
    [J]. BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1992, 70 (3-4): : 228 - 236
  • [10] FALGUEYRET PP, 1993, BIOCHEM PHARMACOL, V45, P978